Quazepam
From Wikipedia, the free encyclopedia
 |
|
 |
|
|
Quazepam
|
|
| Systematic (IUPAC) name | |
| 7-chloro-5-(o-fluorophenyl)-1,3- dihydro-1-(2,2,2-trifluoroethyl)- 2H-1,4-benzodiazepin-2-thione |
|
| Identifiers | |
| CAS number | |
| ATC code | N05 |
| PubChem | |
| DrugBank | |
| Chemical data | |
| Formula | C17H11ClF4N2S |
| Mol. mass | 386.795 g/mol |
| Pharmacokinetic data | |
| Bioavailability | 29–35% |
| Metabolism | Hepatic |
| Half life | 39 hours |
| Excretion | Renal |
| Therapeutic considerations | |
| Pregnancy cat. | |
| Legal status | |
| Routes | Oral |
Quazepam (marketed under brand names Doral, Dormalin) is a drug which is a benzodiazepine derivative. Quazepam induces impairment of motor function and has hypnotic properties.[1]
Quazepam is used to treat insomnia. Usual dosage is 7.5 to 15 mg orally at bedtime. Side effects include drowsiness, loss of coordination, unsteady gait, dizziness, lightheadedness, and slurred speech. It is long-acting benzodiazepine.
[edit] Elderly
An extensive review of the medical literature regarding the management of insomnia and the elderly found that there is considerable evidence of the effectiveness and durability of non-drug treatments for insomnia in adults of all ages and that these interventions are underutilized. Compared with the benzodiazepines including quazepam, the nonbenzodiazepine sedative-hypnotics appeared to offer few, if any, significant clinical advantages in efficacy or tolerability in elderly persons. It was found that newer agents with novel mechanisms of action and improved safety profiles, such as the melatonin agonists, hold promise for the management of chronic insomnia in elderly people. Long-term use of sedative-hypnotics for insomnia lacks an evidence base and has traditionally been discouraged for reasons that include concerns about such potential adverse drug effects as cognitive impairment (anterograde amnesia), daytime sedation, motor incoordination, and increased risk of motor vehicle accidents and falls. In addition, the effectiveness and safety of long-term use of these agents remain to be determined. It was concluded that more research is needed to evaluate the long-term effects of treatment and the most appropriate management strategy for elderly persons with chronic insomnia.[2]
[edit] References
- ^ Yasui M; Kato A, Kanemasa T, Murata S, Nishitomi K, Koike K, Tai N, Shinohara S, Tokomura M, Horiuchi M, Abe K. (Jun 2005). "[Pharmacological profiles of benzodiazepinergic hypnotics and correlations with receptor subtypes]" 25 (3): 143–51. PMID 16045197.
- ^ Bain KT (Jun 2006). "Management of chronic insomnia in elderly persons". Am J Geriatr Pharmacother 4 (2): 168–92. doi:. PMID 16860264.
[edit] External links
|
|||||||||||||||||||||||||||||
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
